Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. - Wikidata - awgldk - TriplyDB

Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.

Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.

http://www.wikidata.org/entity/Q39696423

about

Novel epigenetic target therapy for prostate cancer: a preclinical study Geriatric considerations in the treatment of advanced prostate cancer Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida.Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases Gleason 6 Prostate Cancer: Translating Biology into Population Health.The challenge of cancer in middle-income countries with an ageing population: Mexico as a case study.Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials Impact of Age, Race and Socio-economic Status on Temporal Trends in Late-Stage Prostate Cancer Diagnosis in Florida.Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review.Temporal changes in the clinical approach to diagnosing prostate cancer Impact of age on clinical presentation, treatment, and cancer-specific survival of patients with small-cell carcinoma of the prostate.Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer.CAG Repeat Number in the Androgen Receptor Gene and Prostate Cancer.Clinicopathological and Prognostic Factors in 106 Prostate Cancer Patients Aged ≤55 Years: A Single-Center Study in China.Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men.Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions.Challenges of managing elderly men with prostate cancer.Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.An early-detection programme for prostate cancer in Saudi men: A call from a tertiary-care centre in the Eastern province.Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan.The implications of ageing and life expectancy in prostate cancer treatment.Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.Treatment of Metastatic Prostate Cancer in Older Adults.Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms.Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy.Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation.(223)Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature.Active Surveillance in Younger Men With Prostate Cancer.Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening.Docetaxel in very elderly men with metastatic castration-resistant prostate cancer.Perspectives on the clinical management of localized prostate cancer.The benefits of risk assessment tools for prostate cancer.Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.It is time to start active treatment in senior adults with prostate cancer.

P2860

Q27330048-C30BC9D4-5FF3-4FBD-8C1A-D08327A572CF Q33598327-58D3183F-C09A-406B-9CE8-60F3B2FCE6DD Q33676037-EB2B29D4-422F-4FBE-8574-67EA60B69A95 Q33693397-623B9D16-EE53-409C-98F3-72AC4FD2458D Q33720164-55BEA654-23B5-4898-9606-AC2BFE077E15 Q34132305-DE986B32-4931-4E57-8483-D7EE5646E99F Q34470640-79C9449F-7361-47F4-AE93-A496BE6AE3C5 Q35619356-2C3092C5-1587-46E2-B4E1-C2FF025BDE54 Q36175852-E9E08558-6AA8-4AE6-BA54-A40D8E8A2B5C Q36346584-45933CC5-7906-4786-BBEA-48E993694951 Q36382576-0E4B09B2-7877-4C07-B4B0-7DC4BBD53B2D Q36520528-256321A3-DE5C-4B3B-A00F-1645468BB37D Q37027412-38D9918E-A11D-4F29-91D3-3AC459F4FC5F Q37043425-BAA1FC95-06B7-4955-A00D-2134BFFB554D Q37181453-D6D01736-B8A3-494A-9F66-46F620B10F67 Q37368324-F864218B-5D81-4364-B5A0-8D5AB77918C0 Q37408547-ACEF9B3B-E319-4C57-8E34-8F9A9F7CC5AA Q37455240-76461591-8162-4D23-AD81-D0A226473E80 Q37538483-3F3BA462-1D80-4ACD-AEC6-9F2EC527AB68 Q38211358-68EA0505-FF7D-4947-9E0B-4C7C78594822 Q38267175-C7AD69FE-F9AC-47EF-A83B-F4B73E89BFE7 Q38399938-E8F21BB0-57B7-4276-9DE2-D5DE231D77F7 Q38505558-A862A3E4-29CF-4F73-8627-70368D84C150 Q38736557-F8CD8C20-F4ED-41DA-8153-25AAF4199920 Q38784043-C1E47344-1C33-4FE3-82B6-F64402912CEE Q38841385-575A92C2-90D8-4720-A035-1FFAA15E7965 Q38944255-B6F67C23-C52D-47AC-863F-BCD2EC32AE45 Q39062508-31D0A5CE-3437-49E5-9F2B-5DF2DAE875DE Q39331992-02720032-BE66-49A9-9C06-7F8341B22493 Q39428665-607127A8-D717-44A1-AA89-09338B984209 Q40073452-0ACD5249-2CA2-4123-9002-316B4ADF8520 Q40271880-2E772B6D-4FD1-47F7-9901-1AB9EC17389D Q40820466-4A8813E6-65D2-41B7-9EFD-832769ECAFAB Q40902626-A1793E88-8582-41B9-92D7-3D1168FA766E Q40967992-6C5E452B-4A30-4C0D-AC2E-83C7657087D8 Q41275386-7E1036DF-E4F3-4675-BAC8-7255C19EDF0C Q41896776-13A63410-4867-4AD7-91B8-C1A978575BE5 Q42391610-3B20B1A6-3F59-4936-8D32-35472A860446 Q43726825-3CBAFA8E-129E-4541-BC50-B3F196D420AE Q44102241-66C23DF4-7839-421D-83AB-37DEA0AC1EF4

P2860

Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.

http://www.wikidata.org/entity/Q39696423

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Prostate cancer in the elderly ...... nd disease-specific mortality.

@en

Prostate cancer in the elderly ...... nd disease-specific mortality.

@nl

type

label

Prostate cancer in the elderly ...... nd disease-specific mortality.

@en

Prostate cancer in the elderly ...... nd disease-specific mortality.

@nl

prefLabel

Prostate cancer in the elderly ...... nd disease-specific mortality.

@en

Prostate cancer in the elderly ...... nd disease-specific mortality.

@nl

P1433

Q39696423-328A6A12-33A9-4446-8493-6B6221A1200C

P1476

Q39696423-4B4F15B4-3326-4CAC-98D5-E7185A36BB8F

P2093

Q39696423-1449363D-F025-42C1-866B-F469EB024FF5

Q39696423-BBB8B91F-7D06-4E83-AB73-1F64FC64F583

Q39696423-BC518F18-CB7F-449D-A135-A8CCED5625A2

Q39696423-E9926AD6-3719-4D56-B931-E75D6B77F28E

Q39696423-F88167F0-0C9D-41AA-B9BF-FAFFA4499827

P2860

Q39696423-040E15B3-50C6-4446-813A-36E932D48F67

Q39696423-09E67C93-129C-413B-BA69-3C19EA2AC277

Q39696423-281F15EA-E309-44B6-A6D7-B283D719E703

Q39696423-3735EB4D-596E-4CC8-9C6B-4FAB5B6CCFC1

Q39696423-3F902A18-F08D-4EA5-AA77-6597F9EE927A

Q39696423-8ED3C58F-A6DD-41F4-AEE0-CB4BB8189C60

Q39696423-CF94F86E-C53C-4186-A427-CC2F9592DF50

Q39696423-FBE11D76-3C59-41D8-ACB4-383E8F2606B3

P304

Q39696423-4F770962-5D67-4B56-A1A6-5EB762E01562

P31

Q39696423-C12826D8-7D93-43FE-A3B7-4D65771AB7E2

P356

Q39696423-1C55E327-0714-435E-B3D3-EEE332B8AB0D

P407

Q39696423-5369EAC8-1E61-4264-98A1-6339E77A767C

P433

Q39696423-66F428D9-681A-4B92-B408-F6F61F9DC9F0

P478

Q39696423-D50EDB15-9587-40F1-8807-AA4ADFA90FD1

P577

Q39696423-DDBB74F4-9858-410D-97AA-819087D51107

P5875

Q39696423-22560040-9643-4042-8A99-C36A5FFBC8FC

P698

Q39696423-42F836EA-CE10-4819-8906-C1ADA9509D5C

P356

P1433

P1476

Prostate cancer in the elderly ...... nd disease-specific mortality.

@en

P2093

Dragan Golijanin

http://www.w3.org/2001/XMLSchema#string

Edward M Messing

http://www.w3.org/2001/XMLSchema#string

Emil Scosyrev

http://www.w3.org/2001/XMLSchema#string

Guan Wu

http://www.w3.org/2001/XMLSchema#string

Supriya Mohile

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Screening and prostate-cancer mortality in a randomized European study

Cancer screening in elderly patients: a framework for individualized decision making.

Impact of age at diagnosis on prostate cancer treatment and survival

Comorbidity and mortality results from a randomized prostate cancer screening trial.

Impact of comorbidity on survival among men with localized prostate cancer.

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.

Radical prostatectomy versus watchful waiting in early prostate cancer

P304

3062-3070

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.26392

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51725679

http://www.w3.org/2001/XMLSchema#string

P698

22006014

http://www.w3.org/2001/XMLSchema#string